Corcept Therapeutics Incorporated Company Profile (NASDAQ:CORT)

About Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated logoCorcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:CORT
  • CUSIP: 21835210
  • Web: www.corcept.com
Capitalization:
  • Market Cap: $1.35 billion
  • Outstanding Shares: 113,187,000
Average Prices:
  • 50 Day Moving Avg: $10.21
  • 200 Day Moving Avg: $9.01
  • 52 Week Range: $4.95 - $12.23
P/E:
  • Trailing P/E Ratio: 109.08
  • Foreward P/E Ratio: 23.31
  • P/E Growth: 0.76
Sales & Book Value:
  • Annual Revenue: $92.86 million
  • Price / Sales: 14.49
  • Book Value: $0.44 per share
  • Price / Book: 27.02
Profitability:
  • EBIDTA: $14.4 million
  • Net Margins: 6.21%
  • Return on Equity: 28.11%
  • Return on Assets: 11.96%
Debt:
  • Current Ratio: 1.89%
  • Quick Ratio: 1.81%
Misc:
  • Average Volume: 1.02 million shs.
  • Beta: 1.72
  • Short Ratio: 6.14
 

Frequently Asked Questions for Corcept Therapeutics Incorporated (NASDAQ:CORT)

What is Corcept Therapeutics Incorporated's stock symbol?

Corcept Therapeutics Incorporated trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics Incorporated's earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings data on Monday, May, 1st. The company reported $0.04 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.03 by $0.01. The business earned $27.60 million during the quarter, compared to analyst estimates of $25.53 million. Corcept Therapeutics Incorporated had a return on equity of 28.11% and a net margin of 6.21%. The business's revenue for the quarter was up 71.9% on a year-over-year basis. View Corcept Therapeutics Incorporated's Earnings History.

When will Corcept Therapeutics Incorporated make its next earnings announcement?

Corcept Therapeutics Incorporated is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Corcept Therapeutics Incorporated.

Where is Corcept Therapeutics Incorporated's stock going? Where will Corcept Therapeutics Incorporated's stock price be in 2017?

4 equities research analysts have issued twelve-month price objectives for Corcept Therapeutics Incorporated's stock. Their predictions range from $7.00 to $18.00. On average, they anticipate Corcept Therapeutics Incorporated's share price to reach $12.75 in the next year. View Analyst Ratings for Corcept Therapeutics Incorporated.

Are investors shorting Corcept Therapeutics Incorporated?

Corcept Therapeutics Incorporated saw a increase in short interest in April. As of April 13th, there was short interest totalling 6,325,479 shares, an increase of 5.7% from the March 31st total of 5,985,264 shares. Based on an average daily volume of 728,448 shares, the days-to-cover ratio is currently 8.7 days.

Who are some of Corcept Therapeutics Incorporated's key competitors?

Who owns Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock is owned by many different of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (6.93%), LONGITUDE CAPITAL PARTNERS, LLC (5.70%), Vanguard Group Inc. (3.31%), Renaissance Technologies LLC (1.64%), State Street Corp (1.42%) and Morgan Stanley (1.16%). Company insiders that own Corcept Therapeutics Incorporated stock include Daniel Bradbury, David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright and Steven Lo. View Institutional Ownership Trends for Corcept Therapeutics Incorporated.

Who sold Corcept Therapeutics Incorporated stock? Who is selling Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Ingalls & Snyder LLC, Menta Capital LLC, EAM Investors LLC, Russell Investments Group Ltd., Oxford Asset Management, Credit Suisse AG and Public Employees Retirement Association of Colorado. Company insiders that have sold Corcept Therapeutics Incorporated stock in the last year include James N Wilson, Joseph K Belanoff and Patrick G Enright. View Insider Buying and Selling for Corcept Therapeutics Incorporated.

Who bought Corcept Therapeutics Incorporated stock? Who is buying Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Bank of New York Mellon Corp, Driehaus Capital Management LLC, Vanguard Group Inc., Dimensional Fund Advisors LP, Renaissance Technologies LLC, State Street Corp and Bogle Investment Management L P DE. Company insiders that have bought Corcept Therapeutics Incorporated stock in the last two years include G Leonard Baker Jr and Gary Charles Robb. View Insider Buying and Selling for Corcept Therapeutics Incorporated.

How do I buy Corcept Therapeutics Incorporated stock?

Shares of Corcept Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Corcept Therapeutics Incorporated stock cost?

One share of Corcept Therapeutics Incorporated stock can currently be purchased for approximately $11.89.

Analyst Ratings

Consensus Ratings for Corcept Therapeutics Incorporated (NASDAQ:CORT) (?)
Ratings Breakdown: 1 Sell Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $12.75 (7.23% upside)

Analysts' Ratings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00LowView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$14.00N/AView Rating Details
12/20/2016Janney Montgomery ScottInitiated CoverageSell$7.00N/AView Rating Details
11/2/2016FBR & CoSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 5/22/2015 forward)

Earnings

Earnings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Earnings by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Earnings History by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017        
5/1/2017Q1 2017$0.03$0.04$25.53 million$27.60 millionViewListenView Earnings Details
3/6/2017Q4 2016$0.04$0.04$23.85 million$23.81 millionViewN/AView Earnings Details
11/1/2016Q316$0.01$0.02$21.24 million$21.70 millionViewN/AView Earnings Details
1/28/2016Q415($0.02)$0.01$15.50 million$15.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.02)($0.01)$13.90 million$13.30 millionViewN/AView Earnings Details
8/5/2015Q215($0.04)($0.02)$11.67 million$11.96 millionViewN/AView Earnings Details
5/7/2015Q115($0.04)($0.05)$10.50 million$10.10 millionViewN/AView Earnings Details
3/4/2015Q414($0.06)($0.03)$9.10 million$9.01 millionViewN/AView Earnings Details
11/4/2014Q214($0.07)($0.05)$7.62 million$7.28 millionViewN/AView Earnings Details
5/7/2014Q114($0.10)($0.13)$5.01 million$4.41 millionViewN/AView Earnings Details
3/5/2014Q413($0.10)($0.11)$4.01 million$4.10 millionViewN/AView Earnings Details
1/30/2014Q4($0.12)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$2.70 million$2.60 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.10)$2.72 million$1.90 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$2.48 million$1.72 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.09)($0.09)$1.50 million$1.38 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Current Year EPS Consensus Estimate: $0.26 EPS
Next Year EPS Consensus Estimate: $0.51 EPS

Dividends

Dividend History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 43.57%
Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Institutional Ownership by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/4/2017Gary Charles RobbCFOBuy5,600$9.75$54,600.00View SEC Filing  
3/16/2017Patrick G. EnrightDirectorSell269,955$9.94$2,683,352.70View SEC Filing  
3/15/2017Patrick G EnrightDirectorSell600,000$10.15$6,090,000.00View SEC Filing  
3/8/2017Patrick G EnrightDirectorSell750,000$9.75$7,312,500.00View SEC Filing  
2/27/2017Patrick G EnrightDirectorSell2,500,000$8.81$22,025,000.00View SEC Filing  
11/25/2016Patrick G EnrightDirectorSell36,941$9.34$345,028.94View SEC Filing  
11/21/2016Patrick G EnrightDirectorSell544,100$9.56$5,201,596.00View SEC Filing  
11/16/2016Patrick G EnrightDirectorSell174,847$9.55$1,669,788.85View SEC Filing  
11/11/2016James N WilsonDirectorSell158,812$8.51$1,351,490.12View SEC Filing  
11/11/2016Joseph K BelanoffInsiderSell500,000$8.98$4,490,000.00View SEC Filing  
11/7/2016Joseph K BelanoffCEOSell500,000$8.31$4,155,000.00View SEC Filing  
5/10/2016G Leonard Baker JrDirectorBuy100,000$4.88$488,000.00View SEC Filing  
1/6/2016James N WilsonDirectorSell1,188$4.90$5,821.20View SEC Filing  
12/10/2015Daniel BradburyDirectorSell20,000$4.85$97,000.00View SEC Filing  
11/24/2015Daniel BradburyDirectorSell40,000$5.00$200,000.00View SEC Filing  
11/12/2015James N WilsonDirectorSell20,000$4.90$98,000.00View SEC Filing  
11/2/2015Steven LoVPSell12,500$4.00$50,000.00View SEC Filing  
10/13/2015Steven LoVPSell53,033$3.82$202,586.06View SEC Filing  
10/7/2015Steven LoVPSell5,300$4.00$21,200.00View SEC Filing  
10/6/2015Steven LoVPSell50,000$3.76$188,000.00View SEC Filing  
9/16/2015Daniel BradburyDirectorSell20,000$4.96$99,200.00View SEC Filing  
9/1/2015James N WilsonDirectorSell10,000$4.90$49,000.00View SEC Filing  
8/27/2015Daniel BradburyDirectorSell20,000$4.76$95,200.00View SEC Filing  
7/21/2015Daniel BradburyDirectorSell10,000$4.98$49,800.00View SEC Filing  
7/20/2015Daniel BradburyDirectorSell10,000$5.32$53,200.00View SEC Filing  
7/8/2015David L MahoneyDirectorSell33,828$5.74$194,172.72View SEC Filing  
7/1/2015James N WilsonDirectorSell10,000$6.06$60,600.00View SEC Filing  
6/24/2015Daniel BradburyDirectorSell20,000$6.75$135,000.00View SEC Filing  
6/23/2015Daniel BradburyDirectorSell10,000$6.92$69,200.00View SEC Filing  
6/2/2015James N WilsonDirectorSell10,000$6.13$61,300.00View SEC Filing  
3/24/2015Patrick G EnrightDirectorSell1,089,745$5.75$6,266,033.75View SEC Filing  
3/19/2015Joseph C Cook JrDirectorSell77,200$5.22$402,984.00View SEC Filing  
6/11/2014G Leonard Baker JrDirectorBuy103,386$2.32$239,855.52View SEC Filing  
5/13/2014Joseph Cook, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/12/2014Daniel BradburyDirectorBuy138,925$1.80$250,065.00View SEC Filing  
5/9/2014G Leonard Baker, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/2/2014Longitude Venture Partners L.PDirectorSell250,000$4.11$1,027,500.00View SEC Filing  
4/1/2014Patrick EnrightDirectorSell250,000$4.28$1,070,000.00View SEC Filing  
3/7/2014Longitude Venture Partners L.PDirectorSell250,000$4.00$1,000,000.00View SEC Filing  
3/14/2013Joseph L TurnerDirectorBuy10,000$2.01$20,100.00View SEC Filing  
12/5/2012G Leonard Baker JrDirectorBuy87,131$1.46$127,211.26View SEC Filing  
11/23/2012Daniel BradburyDirectorBuy179,000$1.39$248,810.00View SEC Filing  
11/7/2012G Leonard Baker JrDirectorBuy300,000$1.83$549,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Latest Headlines for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Source:
DateHeadline
finance.yahoo.com logoCorcept Therapeutics Incorporated (CORT)
finance.yahoo.com - May 19 at 8:37 AM
finance.yahoo.com logoETFs with exposure to Corcept Therapeutics, Inc. : May 18, 2017
finance.yahoo.com - May 18 at 4:21 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Given a $18.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - May 15 at 2:34 PM
finance.yahoo.com logoBlog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate
finance.yahoo.com - May 12 at 4:57 PM
finance.yahoo.com logoCorcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : May 10, 2017
finance.yahoo.com - May 10 at 4:36 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) CFO Gary Charles Robb Acquires 5,600 Shares
www.americanbankingnews.com - May 8 at 8:22 PM
americanbankingnews.com logoZacks Investment Research Downgrades Corcept Therapeutics Incorporated (CORT) to Hold
www.americanbankingnews.com - May 8 at 4:16 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 5 at 11:38 AM
finance.yahoo.com logoCorcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress
finance.yahoo.com - May 4 at 4:34 PM
americanbankingnews.com logoTheStreet Downgrades Corcept Therapeutics Incorporated (CORT) to C+
www.americanbankingnews.com - May 3 at 5:56 PM
finance.yahoo.com logoEdited Transcript of CORT earnings conference call or presentation 1-May-17 9:00pm GMT
finance.yahoo.com - May 3 at 4:24 PM
finance.yahoo.com logoCorcept Therapeutics Announces First Quarter 2017 Financial ... - Yahoo Finance
finance.yahoo.com - May 3 at 8:43 AM
americanbankingnews.com logoFavorable News Coverage Somewhat Likely to Affect Corcept Therapeutics (CORT) Share Price
www.americanbankingnews.com - May 3 at 1:01 AM
finance.yahoo.com logoCorcept posts 1Q profit
finance.yahoo.com - May 2 at 7:34 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 2 at 1:03 PM
finance.yahoo.com logoInvestor Network: Corcept Therapeutics Incorporated. to Host Earnings Call
finance.yahoo.com - May 1 at 4:24 PM
finance.yahoo.com logoCorcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
finance.yahoo.com - May 1 at 4:24 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Short Interest Update
www.americanbankingnews.com - April 29 at 11:56 PM
americanbankingnews.com logoCorcept Therapeutics (CORT) Receiving Somewhat Negative Press Coverage, Report Finds
www.americanbankingnews.com - April 29 at 8:28 AM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:17 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Likely to Affect Corcept Therapeutics (CORT) Share Price
www.americanbankingnews.com - April 25 at 5:12 PM
finance.yahoo.com logoCorcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : April 25, 2017
finance.yahoo.com - April 25 at 4:13 PM
finance.yahoo.com logoCorcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
finance.yahoo.com - April 24 at 4:20 PM
finance.yahoo.com logoCorcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : April 24, 2017
finance.yahoo.com - April 24 at 9:27 AM
finance.yahoo.com logoHere's Why Corecept Therapeutics Incorporated Had a Rough Day
finance.yahoo.com - April 21 at 9:32 PM
zacks.com logoNivalis' (NVLS) Shares Down After Merger Deal with Alpine
www.zacks.com - April 20 at 4:35 PM
americanbankingnews.com logoCorcept Therapeutics (CORT) Receives News Impact Score of 0.56
www.americanbankingnews.com - April 20 at 11:53 AM
americanbankingnews.com logoCorcept Therapeutics (CORT) Earns Daily Coverage Optimism Score of -0.22
www.americanbankingnews.com - April 14 at 7:54 AM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 10 at 11:31 AM
finance.yahoo.com logoCorcept (CORT) Up 18% Since Earnings Report: Can It Continue?
finance.yahoo.com - April 7 at 9:07 AM
zacks.com logoCorcept (CORT) Strives to Commercialize Key Drug Korlym
www.zacks.com - March 29 at 4:54 PM
thestreet.com logoFirst Week of November 17th Options Trading For Corcept Therapeutics (CORT)
www.thestreet.com - March 21 at 4:44 PM
americanbankingnews.com logoInsider Selling: Corcept Therapeutics Incorporated (CORT) Director Sells 269,955 Shares of Stock
www.americanbankingnews.com - March 20 at 7:28 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics
finance.yahoo.com - March 17 at 3:53 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Receives Consensus Recommendation of “Hold” from Analysts
www.americanbankingnews.com - March 15 at 1:30 PM
americanbankingnews.com logoPatrick G. Enright Sells 750,000 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - March 10 at 6:18 PM
us.rd.yahoo.com logoCORCEPT THERAPEUTICS INC Financials
us.rd.yahoo.com - March 10 at 5:30 PM
us.rd.yahoo.com logoCorcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance
us.rd.yahoo.com - March 6 at 10:28 AM
biz.yahoo.com logoCORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure
us.rd.yahoo.com - March 6 at 10:27 AM
thestreet.com logoCORT Crosses Above Average Analyst Target
www.thestreet.com - February 27 at 4:13 PM
biz.yahoo.com logoCORCEPT THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financi
biz.yahoo.com - February 13 at 5:06 PM
benzinga.com logoLadenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy - Benzinga
www.benzinga.com - February 2 at 9:52 PM
finance.yahoo.com logoCoverage initiated on Corcept Therapeutics by Ladenburg Thalmann
finance.yahoo.com - February 2 at 4:49 PM
finance.yahoo.com logoEdited Transcript of CORT earnings conference call or presentation 30-Jan-17 10:00pm GMT
finance.yahoo.com - January 31 at 4:54 PM
us.rd.yahoo.com logoCorcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance
us.rd.yahoo.com - January 30 at 5:17 PM
biz.yahoo.com logoPreliminary Q4 2016 Corcept Therapeutics Inc Earnings Release - After Market Close
biz.yahoo.com - January 30 at 7:35 AM
bizjournals.com logoResearch Reports Coverage on Biotech Stocks -- PharmAthene, Corcept Therapeutics, Navidea Biopharma, and Inotek Pharma
www.bizjournals.com - January 25 at 5:36 PM
finance.yahoo.com logoCorcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call
finance.yahoo.com - January 23 at 4:44 PM
us.rd.yahoo.com logo4:13 pm Corcept Therapeutics: Longitude Capital lowers active stake to 10.29% following recent sale of approximately 756k shares
us.rd.yahoo.com - December 15 at 9:51 PM
finance.yahoo.com logo3:37 am Corcept Therapeutics reports data from Phase 1/2 tria of Mifepristone Plus Eribulin; demonstrates encouraging results in triple-negative breast cancer
finance.yahoo.com - December 12 at 12:21 PM

Social

Corcept Therapeutics Incorporated (CORT) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by MarketBeat.com Staff